This article is more than 5 years old. Information may no longer be current.
NY Presbyterian appoints director of experimental therapeutics
Click Here to Manage Email Alerts
Richard D. Carvajal, MD, has been named director of the experimental therapeutics/phase 1 program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center.
Carvajal previously served as director of developmental therapeutics and chair for junior faculty at Memorial Sloan Kettering Cancer Center.
Richard D .Carvajal
Carvajal, who specializes in melanomas, has considerable experience in early-stage clinical trials for patients with advanced cancers. His work focuses on uncommon, difficult-to-treat cancers, such as uveal melanomas, mucosal melanomas and acral melanomas.
“Dr. Carvajal has spearheaded the development of important treatments that have transformed the lives of patients with rare cancers,” Gary Schwartz, MD, professor of medicine at Columbia University Medical Center and chief of the division of hematology/oncology at NewYork-Presbyterian/Columbia, said in a press release. “We are excited to have him on board, with his experience and talent for innovation, and we look forward to his future contributions to patient-centered health care as he leads our experimental therapeutics program. He brings with him a wealth of knowledge on the development of new agents for patients with a wide range of tumor types, including rare cancers.”